6篇
您的检索式：作者名="Rebecca JM"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Capturingand profiling adult hair follicle stem cells显示文摘 | Rebecca JM Yaping L Lee M | 2004 | Nature Biotech2004，22，： | 1 |
| 2 | 显示文摘 | Alexander JM Rebecca JG Michele AL | 2001 | Nature2001，409，6816： | 1 |
| 3 | Proteomic analysis ofcast cuticles from Anopheles gambiae by tandem mass spectrome- try显示文摘 | He N Julianne MB Rebecca JM | 2007 | Insect Biochem Mol Biol2007，37，2： | 1 |
| 4 | Treatment of hyperprolactine- mia:a systematic review and meta-analysis 显示文摘 | Amy TW Rebecca JM Melanie AL | 2012 | Systematic Reviews2012，1，： | 1 |
| 5 | An antagonist of the retinoid X receptor re- duces the viability of Trichuris muris in vitro 显示文摘 | Rebecca JM Hurst | 2014 | BMC Infect Dis2014，，14： | 1 |
| 6 | Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies显示文摘The use of immune checkpoint inhibitors(iCls)has increased exponentially in the past decade,although its progress specifically for breast cancer has been modest.The first U.S.Food and Drug Administration approval for ICl in breast cancer came in 2019,eight years after the first-ever approval of an ICl.At present,current indications for ICls are relevant only to a subset of patients with triple-negative breast cancer,or those displaying high microsatellite instability or deficiency in the mismatch repair protein pathway.With an increasing understanding of the limitations of using ICls,which stem from breast cancer being innately poorly immunogenic,as well as the presence of various intrinsic and acquired resistance pathways,ongoing trials are evaluating different combination therapies to overcome these barriers.In this review,we aim to describe the development timeline of ICls and resistance mechanisms limiting their utility,and summarise the available approaches and ongoing trials relevant to overcoming each resistance mechanism. | Rachel SJ Wong Rebecca JM Ong Joline SJ Lim | 2023 | Cancer Drug Resistance2023，6，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员